Posts tagged: lower

BACKGROUND: The role of different chemokine receptors in the pathogenesis of multiple sclerosis (MS) has been extensively investigated; however, little is known about the difference in the role of chemokine receptors between the pathogenesis of neuromyelitis optica (NMO) and MS. Therefore, we examined the expression of chemokine receptors on peripheral blood lymphocytes (PBL) in MS and NMO. METHODS: We used flow cytometry to analyse lymphocyte subsets in 12 patients with relapsing NMO, 24 with relapsing-remitting MS during relapse, 3 with NMO and 5 with MS during remission.

Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder characterized by optic neuritis and acute myelitis. A parainfectious pathogenesis may play a partial role in the development of this disorder.

It may be possible to save money by treating multiple sclerosis and neuromyelitis optica with lower doses of rituximab, but the result may be a shorter period of effectiveness, according to one study.

Background:  Oxidative stress plays a central role in neuropathology of multiple sclerosis (MS).

OBJECTIVE: To investigate serum uric acid (UA) levels and related clinical characteristics of neuromyelitis optica (NMO). METHODS: The serum uric acid levels were measured in 65 patients with NMO, compared to control groups which were 76 cases with multiple sclerosis (MS), 126 cases with cerebral vascular diseases (CVD) and 130 healthy controls (HC). The disability severity in NMO was assessed by the Expanded Disability Status Scale (EDSS).

Background:  The burden of multiple sclerosis (MS) includes fatigue, depression and worsening of health-related quality of life (HRQOL).

Neuromyelitis optica (NMO) is an uncommon, life-threatening inflammatory demyelinating disorder.